Biondo Investment Advisors LLC Lowers Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Biondo Investment Advisors LLC lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 875 shares of the biopharmaceutical company’s stock after selling 30 shares during the period. Biondo Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $623,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Intact Investment Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $356,000. Principal Financial Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after acquiring an additional 2,828 shares during the last quarter. Golden State Equity Partners increased its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% during the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after acquiring an additional 1,272 shares in the last quarter. Fagan Associates Inc. raised its position in shares of Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock worth $9,205,000 after purchasing an additional 3,832 shares during the last quarter. Finally, ABC Arbitrage SA bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $1,510,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on REGN. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Bank of America reissued an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Finally, Bernstein Bank dropped their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Up 0.2 %

REGN stock opened at $637.36 on Friday. The business’s 50-day moving average price is $683.88 and its 200-day moving average price is $800.34. The stock has a market cap of $69.68 billion, a P/E ratio of 16.65, a PEG ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $629.02 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $11.86 earnings per share. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.55%. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.